thinkpool

 VGX Pharmaceuticals announced today that the Company has initiated manufacturing of VGX-1027, its lead drug candidate for the treatment of rheumatoid arthritis and psoriasis. VGX-1027 is a novel orally-active, small-molecule drug compound with broad anti-inflammatory properties.
VGX Pharmaceuticals는 오늘 회사가 류머티즘 관절염과 건선을 앞장서 치료하기 위한 후보로 VGX-1027을 제조하기 시작했다고 발표했다. VGX-1027은 구강복용의 광범위한 항 염증 특징을 갖고 있는 작은 분자의 약이다.

Inflammatory diseases including rheumatoid arthritis, psoriasis, colitis, and type I diabetes represent major medical problems. For instance, over 2.1 Million and 4.5 Million people suffer from rheumatoid arthritis and psoriasis in the U.S., respectively.
류머티즘 관절염과 건선, colitis, 1번 유형 당뇨병을 포함하는 염증 병은 중요한 의학적 문제를 나타내고있다. 예를 들어 미국의 210만 명이나 450만 명의 사람들이 각각 류머티즘 관절염과 건선으로 고통받고 있다.

VGX-1027 is an immune modulator that inhibits production of several pro-inflammatory cytokines that are responsible for the damaging effects of inflammatory diseases. Pre-clinical studies have shown that VGX-1027 is effective in inhibiting these cytokines in cell culture, and has shown efficacy in animal disease models.
VGX-1027은 염증 병의 파괴적 영향에 일조하는, 몇몇 염증을 일으키는 세포질을 만들어내는 것을 막아주는 면역성 조절자이다. 전 의학 연구에 의하면 VGX-1027이 세포에 이런 세포질들을 막아주는 데 효과적임을 발견했으며, 동물 당뇨병 실험에서도 효과를 보였다.

“This is a major development for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis,” says J. Joseph Kim, Ph.D., President and CEO of VGX Pharmaceuticals. “VGX-1027 has shown therapeutic effects against various inflammatory diseases such as RA, type I diabetes, psoriasis, and colitis in pre-clinical animal models.
“이것은 류머티즘 관절염과 건선과 같은 염증 병을 치료하는 데 큰 발전이다” VGX Pharmaceuticals의 회장이자 CEO인 조셉 김이 말했다. “VGX 1027은 RA, 1번 당뇨병, psoriasis, colitis와 같은 병에 대해 동물 실험에서 치료 효과를 보였다.

Currently, there are very few safe, orally available treatment options for these diseases. VGX-1027 represents a new class of an orally active immune modulator for these diseases. This program represents VGX Pharmaceutical’s new entry into the important inflammatory disease market with a lead drug candidate with several potential advantages over currently available treatment options,” said Dr. Kim.
현재, 이러한 질병을 위한 구강복용이 가능한 안전한 치료 선택은 매우 적다. VGX1027은 이런 질병들에 대한 구강복용의 면역성 조절자의 새로운 계층을 대표한다. 이 프로그램은 현재 가능한 치료 선택에 대해 여러 가능성 있는 이익과 함께 주요 약 후보로, VGX 제조회사의 중요한 염증 질병 시장으로의 진입을 의미한다.   

VGX Pharmaceuticals plans to manufacture two different formulations of VGX-1027, an oral tablet and a topical cream, to be investigated in separate clinical trials. The oral tablet form is planned to be used for systemic treatment of both RA and psoriasis, and the topical cream is planned to be used for local treatment of moderate psoriasis.
VGX 제조회사는 VGX1027의 두 가지 다른 공식 표시를 제조하려고 한다. oral tablet과 topical cream인데, 따로 의학적 시도에서 조사될 것이다. oral tablet form은 RA와 psoriasis의 체계적인 치료에 사용될 것으로 되어 있고, topical cream은 moderate psoriasis의 국부적 치료에 사용될 것으로 계획돼 있다.

The Company plans to file two Investigational New Drug Applications (IND’s) for VGX-1027 in early 2007 to support the initiation of Phase I clinical trials during first quarter 2007.
회사는 2007년 1분기에 1단계 의학 시도를 뒷받침하기 위하여 2007년 초에 vgx-1027을 위한 두 개의 IND's를 보존할 계획이다.

 VGX Pharmaceuticals Initiates Manufacturing of VGX-1027 for Phase I Clinical Trials

Blue Bell, PA – April 28, 2006 –   

VGX Pharmaceuticals announced today that the Company has initiated manufacturing of VGX-1027, its lead drug candidate for the treatment of rheumatoid arthritis and psoriasis. VGX-1027 is a novel orally-active, small-molecule drug compound with broad anti-inflammatory properties.

Inflammatory diseases including rheumatoid arthritis, psoriasis, colitis, and type I diabetes represent major medical problems. For instance, over 2.1 Million and 4.5 Million people suffer from rheumatoid arthritis and psoriasis in the U.S., respectively.

VGX-1027 is an immune modulator that inhibits production of several pro-inflammatory cytokines that are responsible for the damaging effects of inflammatory diseases. Pre-clinical studies have shown that VGX-1027 is effective in inhibiting these cytokines in cell culture, and has shown efficacy in animal disease models.

“This is a major development for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis,” says J. Joseph Kim, Ph.D., President and CEO of VGX Pharmaceuticals. “VGX-1027 has shown therapeutic effects against various inflammatory diseases such as RA, type I diabetes, psoriasis, and colitis in pre-clinical animal models. Currently, there are very few safe, orally available treatment options for these diseases. VGX-1027 represents a new class of an orally active immune modulator for these diseases. This program represents VGX Pharmaceutical’s new entry into the important inflammatory disease market with a lead drug candidate with several potential advantages over currently available treatment options,” said Dr. Kim.

VGX Pharmaceuticals plans to manufacture two different formulations of VGX-1027, an oral tablet and a topical cream, to be investigated in separate clinical trials. The oral tablet form is planned to be used for systemic treatment of both RA and psoriasis, and the topical cream is planned to be used for local treatment of moderate psoriasis.

The Company plans to file two Investigational New Drug Applications (IND’s) for VGX-1027 in early 2007 to support the initiation of Phase I clinical trials during first quarter 2007.

VGX인터 A011000   거래소  (액면가 : 1,000)    * 05월 02일 09시 24분 데이터    현재가 44,450  시가 44,500  52주 최고 109,000  전일비 ▲ 350  고가 45,200  52주 최저 1,122  거래량 15,705  저가 44,000  총주식수 3,793

시나비전 A038500   코스닥  (액면가 : 500)      * 05월 02일 08시 58분 데이터    현재가 1,210  시가 0  52주 최고   전일비 0  고가 0  52주 최저   거래량 1,672  저가 0  총주식수 43,558,484

키이스트 A054780   코스닥  (액면가 : 500)      * 05월 02일 08시 58분 데이터    현재가 44,000  시가 0  52주 최고   전일비 0  고가 0  52주 최저   거래량 0  저가 0  총주식수 3,858,164

엠에이티 A080440   코스닥  (액면가 : 500)      * 05월 02일 08시 58분 데이터    현재가 2,640  시가 0  52주 최고   전일비 0  고가 0  52주 최저   거래량 0  저가 0  총주식수 12,394,320

VGX인터 A011000   거래소  (액면가 : 1,000)    * 05월 02일 08시 58분 데이터    현재가 44,100  시가 0  52주 최고 109,000  전일비 0  고가 0  52주 최저 1,122  거래량 5  저가 0  총주식수 3,793